Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | NPY4R | P50391 | 6/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.38 |
| ▸ | NPY1R | P25929 | 4/20 | 0.38 |
| ▸ | NPY2R | P49146 | 2/20 | 0.38 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.38 |
| ▸ | NMT2 | O60551 | 2/20 | 0.36 |
| ▸ | NMT1 | P30419 | 2/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | FURIN | P09958 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27432486 | 0.94 | FAP (0.46) | FAPROCK2NPY4RNPY5RNPY1R | |
| SCHEMBL22952275 | 0.94 | FAP (0.44) | FAPROCK2NPY4RNPY5RNPY1R | |
| SCHEMBL18820196 | 0.92 | FAP (0.44) | FAPROCK2NPY4RNPY5RNPY1R | |
| SCHEMBL9943152 | 0.92 | FAP (0.47) | FAPROCK2NPY4RNPY5RNPY1R | |
| SCHEMBL21416485 | 0.92 | FAP (0.44) | FAPROCK2NPY4RNPY5RNPY1R | |
| SCHEMBL24520454 | 0.92 | FAP (0.47) | FAPROCK2NPY4RNPY5RNPY1R | |
| SCHEMBL20808481 | 0.92 | FAP (0.44) | FAPROCK2NPY4RNPY5RNPY1R | |
| SCHEMBL16266184 | 0.92 | FAP (0.44) | FAPROCK2NPY4RNPY5RNPY1R | |
| SCHEMBL16266214 | 0.92 | FAP (0.44) | FAPROCK2NPY4RNPY5RNPY1R | |
| SCHEMBL15246622 | 0.92 | FAP (0.44) | FAPROCK2NPY4RNPY5RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10683327-B2 | Compounds, linker-drugs and ligand-drug conjugates | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2020-06-16 | — | — | US | disclosed |
| US-10618935-B2 | Antibody-drug conjugate (ADC) and method for forming the same | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2020-04-14 | — | — | US | disclosed |
| US-20190106459-A1 | COMPOUNDS, LINKER-DRUGS AND LIGAND-DRUG CONJUGATES | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2019-04-11 | — | — | US | disclosed |
| US-10233212-B2 | Compounds, linker-drugs and ligand-drug conjugates | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2019-03-19 | — | — | US | disclosed |
| US-20180016300-A1 | COMPOUNDS, LINKER-DRUGS AND LIGAND-DRUG CONJUGATES | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2018-01-18 | — | — | US | disclosed |
| US-20170119902-A1 | ANTIBODY-DRUG CONJUGATE (ADC) AND METHOD FOR FORMING THE SAME | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016300-A1 | COMPOUNDS, LINKER-DRUGS AND LIGAND-DRUG CONJUGATES | SLC43A1, HCAR3, SLC7A1 | FAP 3214/4885ROCK2 3131/4885NPY4R 776/4885 |
| US-10683327-B2 | Compounds, linker-drugs and ligand-drug conjugates | SLC43A1, HCAR3, SLC7A1 | FAP 3214/4885ROCK2 3131/4885NPY4R 776/4885 |
| US-10233212-B2 | Compounds, linker-drugs and ligand-drug conjugates | SLC43A1, HCAR3, SLC7A1 | FAP 3214/4885ROCK2 3131/4885NPY4R 776/4885 |
| US-20170119902-A1 | ANTIBODY-DRUG CONJUGATE (ADC) AND METHOD FOR FORMING THE SAME | DNPEP, DLST, DDOST | FAP 1131/4885ROCK2 4544/4885NPY4R 3884/4885 |
| US-10618935-B2 | Antibody-drug conjugate (ADC) and method for forming the same | DNPEP, DLST, DDOST | FAP 1131/4885ROCK2 4544/4885NPY4R 3884/4885 |
| US-20190106459-A1 | COMPOUNDS, LINKER-DRUGS AND LIGAND-DRUG CONJUGATES | SLC43A1, HCAR3, SLC7A1 | FAP 3214/4885ROCK2 3131/4885NPY4R 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.